Oncovista Innovative Therapies Stock Buy Hold or Sell Recommendation
OVIT Stock | USD 0.0001 0.00 0.00% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding OncoVista Innovative Therapies is 'Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell OncoVista Innovative Therapies given historical horizon and risk tolerance towards OncoVista Innovative. When Macroaxis issues a 'buy' or 'sell' recommendation for OncoVista Innovative Therapies, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out OncoVista Innovative Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as OncoVista and provide practical buy, sell, or hold advice based on investors' constraints. OncoVista Innovative Therapies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
OncoVista |
Execute OncoVista Innovative Buy or Sell Advice
The OncoVista recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on OncoVista Innovative Therapies. Macroaxis does not own or have any residual interests in OncoVista Innovative Therapies or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute OncoVista Innovative's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
Not Rated
OncoVista Innovative Trading Alerts and Improvement Suggestions
OncoVista Innovative generated a negative expected return over the last 90 days | |
OncoVista Innovative has some characteristics of a very speculative penny stock | |
OncoVista Innovative Therapies currently holds 479.3 K in liabilities. OncoVista Innovative has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist OncoVista Innovative until it has trouble settling it off, either with new capital or with free cash flow. So, OncoVista Innovative's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like OncoVista Innovative sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for OncoVista to invest in growth at high rates of return. When we think about OncoVista Innovative's use of debt, we should always consider it together with cash and equity. | |
Net Loss for the year was (2.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
OncoVista Innovative Therapies currently holds about 61.27 K in cash with (232.38 K) of positive cash flow from operations. |
OncoVista Innovative current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. OncoVista analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. OncoVista analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
OncoVista Innovative Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to OncoVista Innovative or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that OncoVista Innovative's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a OncoVista pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
OncoVista Innovative Volatility Alert
At this time OncoVista Innovative Therapies exhibits very low volatility. OncoVista Innovative Therapies appears to be a penny stock. Although OncoVista Innovative Therapies may be, in fact, a solid short-term or long term investment, many penny pink sheets are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in OncoVista Innovative Therapies or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on OncoVista instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.OncoVista Innovative Fundamentals Vs Peers
Comparing OncoVista Innovative's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze OncoVista Innovative's direct or indirect competition across all of the common fundamentals between OncoVista Innovative and the related equities. This way, we can detect undervalued stocks with similar characteristics as OncoVista Innovative or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of OncoVista Innovative's fundamental indicators could also be used in its relative valuation, which is a method of valuing OncoVista Innovative by comparing valuation metrics with those of similar companies.
Better Than Average | Worse Than Average | Compare OncoVista Innovative to competition |
Fundamentals | OncoVista Innovative | Peer Average |
Return On Asset | -23.58 | -0.14 |
Current Valuation | 852.92 K | 16.62 B |
Shares Outstanding | 23.56 M | 571.82 M |
Price To Earning | (0.12) X | 28.72 X |
Price To Book | 26.09 X | 9.51 X |
EBITDA | (3.4 M) | 3.9 B |
Net Income | (2.54 M) | 570.98 M |
Cash And Equivalents | 61.27 K | 2.7 B |
Total Debt | 479.3 K | 5.32 B |
Current Ratio | 0.01 X | 2.16 X |
Book Value Per Share | (0.28) X | 1.93 K |
Cash Flow From Operations | (232.38 K) | 971.22 M |
Earnings Per Share | (0.15) X | 3.12 X |
Number Of Employees | 2 | 18.84 K |
Beta | -51.97 | -0.15 |
Market Capitalization | 558.34 K | 19.03 B |
Total Asset | 12.51 K | 29.47 B |
Retained Earnings | (27.6 M) | 9.33 B |
Working Capital | (5.89 M) | 1.48 B |
Current Asset | 61 K | 9.34 B |
Current Liabilities | 5.95 M | 7.9 B |
Net Asset | 12.51 K |
OncoVista Innovative Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as OncoVista . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Rate Of Daily Change | 1.0 | |||
Day Median Price | 1.0E-4 | |||
Day Typical Price | 1.0E-4 |
About OncoVista Innovative Buy or Sell Advice
When is the right time to buy or sell OncoVista Innovative Therapies? Buying financial instruments such as OncoVista Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having OncoVista Innovative in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Giant Impact Thematic Idea Now
Giant Impact
An experimental equal-weighted decomposition of large high potential stocks based on Macroaxis scoring framework. The Giant Impact theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Giant Impact Theme or any other thematic opportunities.
View All Next | Launch |
Additional Tools for OncoVista Pink Sheet Analysis
When running OncoVista Innovative's price analysis, check to measure OncoVista Innovative's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoVista Innovative is operating at the current time. Most of OncoVista Innovative's value examination focuses on studying past and present price action to predict the probability of OncoVista Innovative's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoVista Innovative's price. Additionally, you may evaluate how the addition of OncoVista Innovative to your portfolios can decrease your overall portfolio volatility.